(Q24197501)

3

0 references

Donna Gillies

5

0 references

Markus Dold

object named as

Markus Dold

1

0 references

author name string

Chunbo Li

2

0 references

Vesal Khorsand

Cochrane Database of Systematic Reviews

4

0 references

language of work or name

English

0 references

publication date

14 November 2012

0 references

published in

0 references

cites work

Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Treatment of long-term tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Weight Changes With Schizophrenic Psychosis and Psychotropic Drug Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Laboratory Changes with Chlordiazepoxide and Thioridazine, Alone and Combined

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Acute high-dose parenteral haloperidol treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Diazepam in high doses is effective in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Clonazepam and phenobarbital in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Analgesic and euphoric effects of high dose diazepam in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Diazepam in schizophrenia: a preliminary double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Placebo response in refractory tardive akathisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Behavioral side effects of triazolam in psychiatric inpatients: report of five cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Diazepam in tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Beta-blocker supplementation of standard drug treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Clozapine versus typical neuroleptic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Benzodiazepines for psychosis-induced aggression or agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Carbamazepine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Lithium for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Evidence-based pharmacotherapy of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

A revision of the psychiatric rating scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Schizophrenia and employment - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Valproate for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Electroconvulsive therapy for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Dropout rates in randomised antipsychotic drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Benzodiazepines for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006391.PUB2

A reference study of ataraxics. A two-week double blind outpatient evaluation

21 January 2018

1 reference

12 December 2020

Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Rapid tranquilization: antipsychotics or benzodiazepines?

1 reference

12 December 2020

Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients.

1 reference

12 December 2020

Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study

1 reference

12 December 2020

Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties

1 reference

12 December 2020

Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study

1 reference

12 December 2020

Adjunctive benzodiazepines in acute schizophrenia

1 reference

12 December 2020

Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia

1 reference

12 December 2020

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study

1 reference

12 December 2020

Development of a scale for assessment of agitation following traumatic brain injury

1 reference

12 December 2020

Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior

1 reference

12 December 2020

A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia

1 reference

12 December 2020

Treatment of catatonia with low-dose lorazepam

1 reference

12 December 2020

Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients

1 reference

12 December 2020

1 reference

12 December 2020

Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study

1 reference

12 December 2020

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

12 December 2020

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

12 December 2020

Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia

1 reference

12 December 2020

A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation.

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double-blind study.

1 reference

12 December 2020

SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials)

1 reference

12 December 2020

Effects of Control Techniques on Therapeutic Outcome in a Controlled Clinical Trial

1 reference

12 December 2020

A comparative study with benzodiazepines in chronic psychotic patients

1 reference

12 December 2020

Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial

1 reference

12 December 2020

Combined drug treatment of newly hospitalized, acutely ill psychiatric patients.

1 reference

12 December 2020

A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms

1 reference

12 December 2020

Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study

1 reference

12 December 2020

Chlordiazepoxide in the treatment of patients with "activated EEG's".

1 reference

12 December 2020

Benzodiazepines in chronic schizophrenia

1 reference

12 December 2020

Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

1 reference

12 December 2020

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

Effect of minor and major tranquilizers on somatosensory evoked potentials

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine

1 reference

12 December 2020

A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients

1 reference

12 December 2020

Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients

1 reference

12 December 2020

Diazepam treatment of early signs of exacerbation in schizophrenia.

1 reference

12 December 2020

Lorazepam treatment of psychogenic catatonia: an update

1 reference

12 December 2020

A double-blind outpatient study of diazepam (Valium) and placebo

1 reference

12 December 2020

Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis

1 reference

12 December 2020

The use of midazolam in acutely agitated psychiatric patients.

1 reference

12 December 2020

A new tranquilizer: lorazepam (158 cases)

1 reference

12 December 2020

Efficacy of propranolol in neuroleptic-induced akathesia

1 reference

12 December 2020

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

1 reference

12 December 2020

The effects of chlordiazepoxide (librium) in anxiety states. A multi-blind study.

1 reference

12 December 2020

A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients

1 reference

12 December 2020

Itil TM, Keskiner A, Fink M: Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia

1 reference

12 December 2020

COMPARISON OF DIAZEPAM, CHLORPROTHIXENE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC PATIENTS

1 reference

12 December 2020

The effect of benzodiazepines on tardive dyskinesia symptoms

1 reference

12 December 2020

Evidence of ten psychotic syndromes.

1 reference

12 December 2020